Dimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Dimensional Fund Advisors LP purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,114 shares of the company’s stock, valued at approximately $205,000. Dimensional Fund Advisors LP owned approximately 0.08% of Amylyx Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Blue Trust Inc. raised its stake in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after acquiring an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. RPO LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at $46,000. EntryPoint Capital LLC acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $53,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Amylyx Pharmaceuticals during the fourth quarter worth $56,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. HC Wainwright increased their price target on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 6th. Mizuho lifted their price target on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Leerink Partners raised shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.83.

Amylyx Pharmaceuticals Price Performance

Shares of Amylyx Pharmaceuticals stock opened at $4.84 on Friday. The company has a market capitalization of $431.44 million, a price-to-earnings ratio of -1.27 and a beta of -0.60. The business has a fifty day simple moving average of $4.14 and a two-hundred day simple moving average of $4.20. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.03. As a group, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 12,425 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the transaction, the insider now directly owns 194,375 shares of the company’s stock, valued at $674,481.25. The trade was a 6.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bernhardt G. Zeiher bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $37,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 48,980 shares of company stock valued at $168,627. 11.70% of the stock is owned by insiders.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.